

# Treatment of Missing Data in Bayesian Structural Learning: A Simulation Study for Social Science: a case-study of Antimicrobial resistance

Xueija Ke, Madeleine Clarkson, Katherine Keenan & V Anne Smith



Scottish  
Graduate  
School of  
Social  
Science



UK Research  
and Innovation



Holistic Approach To  
Unravel Antibacterial  
Resistance in East Africa


# Outline



- Demonstrate how Bayesian belief networks(BBNs) can be used and interpretate for social science data
- Introduce antimicrobial drug resistance(AMR) as a bio-socially complex phenomenon
- Demonstrate how Bayesian logic is useful for understanding the AMR phenomenon
- Summarise results from a literature review of BBNs in AMR and antibiotic use

- Introduce missing data and three missing mechanisms
- A brief review on how BBNs can be used for dealing with missing data
- Demonstrate a simulation study on comparing the performance of two popular approaches for missing data
- Demonstrate an application on real data - case study of AMR





# How can Bayesian Belief Networks be used in social science?

1. **Variable inference**
2. **Parameter inference**
3. **Structure-learning**

# Variable inference

Probability table for node/variable A


Prob (A) =green	Prob(A) =orange
0.5	0.5

Joint Probability table for mode B

	Prob(B) =pink	Prob(B) =blue
Given A= green	0.6	0.4
Given A= orange	0.3	0.7

Joint Probability table for mode C


	Prob(C) =yellow	Prob(C) =blue
Given A= green	0.1	0.9
Given A= orange	0.9	0.1



# Parameter inference

Probability table for  
node/variable A

Prob (A) =green	Prob(A) =orange
?	?




Joint Probability table for mode B

	Prob(B) =pink	Prob(B) =blue
Given A= green	?	?
Given A= orange	?	?


Joint Probability table for mode C

	Prob(C) =yellow	Prob(C) =blue
Given A= green	?	?
Given A= orange	?	?


# Structure-learning



Bayesian Belief networks  
provide "actionable  
motifs"<sup>1</sup> which guide  
social science inference,  
interpretation and further  
investigation




Bayesian Belief networks  
provide "actionable  
motifs"<sup>1</sup> which guide  
social science inference,  
interpretation and further  
investigation






Bayesian Belief networks  
provide "actionable  
motifs"<sup>1</sup> which guide  
social science inference,  
interpretation and further  
investigation




# Confounders and mediators



## Confounder variable

Is a variable which influences two variables causing a spurious association to between them<sup>2</sup>, **within BBNs is represented by *forks* in a directed graphical network<sup>1</sup>**



## Mediator variable

Is a variable which explains the process through which two variables are related<sup>3</sup>, **within BBNs are represented by nodes within a *chain of arcs* in a directed graphical network<sup>1</sup>**

1. Sethi, T. *et al.* (2018) 'Stewarding antibiotic stewardship in intensive care units with Bayesian artificial intelligence [version 1; peer review: 2 approved with reservations]', *Wellcome Open Research*, 3. doi: 10.12688/wellcomeopenres.14629.1.

2. Pearl, J., (2009). [Simpson's Paradox](#), Confounding, and Collapsibility In *Causality: Models, Reasoning and Inference* (2nd ed.). New York : Cambridge University Press.

3. Pritha Bhandari, 2021 Mediator vs Moderator variables [accessed online] <https://www.scribbr.com/methodology/mediator-vs-moderator/>

# Antimicrobial resistance

- Antimicrobial resistance → Evade or survive treatment
- Resistance is a complex issue:
  - Exposure
  - vertical & horizontal gene transfer [Vikesland et al,2020]
  - Animals - Environment - Human
- **Biosocially complex**
- BBNs → complexity
- limited Use in the AMR literature



# Bayesian logic applied to AMR



$$P(A|B) = \frac{P(B|A)P(A)}{P(B|A)P(A) + P(B|\text{not } A)P(\text{not } A)}$$

# Review of the use of BBN applications in the AMR and antibiotic use literature

## Iterative scoping review<sup>4</sup>:

- Literature landscape - terms “Bayes”, “AMR” and “antibiotics”, “antimicrobial resistance”
- How and What
- ~~Bayesian statistical applications~~
- Boolean searches – *Pearl growing*
- citation tracking

# Review of BBNs in the field of AMR

Paper	Main purpose
(Ge <i>et al.</i> , 2014)	Analyse the association between socioeconomic causal factors of antibiotic use in livestock.
(Ludwig <i>et al.</i> , 2014)	Analyse the associations resistance patterns in pig farming ( <i>E.coli</i> )
(Hartnack <i>et al.</i> , 2014)	Analyse the associations in chicken farming ( <i>Salmonella spp.</i> )
(Hidano <i>et al.</i> , 2015)	Analyse the associations in chicken retail ( <i>E. faecalis</i> )
(Cherry <i>et al.</i> , 2021)	Analyse the associations of cross-resistance patterns and antibiotic use in UTI patients
(Sethi <i>et al.</i> , 2021)	Analyse the (Paediatric ICU) antibiotic sensitivities to develop a tool to replace antibiograms
(Wu <i>et al.</i> , 2020)	Develops a tool for clinicians to appropriately prescribe antibiotics & predict causative pathogen (osteomyelitis)
TREAT CPN	Develops a tool for clinicians to appropriately prescribe antibiotics (multiple pathogens)
(Lucas <i>et al.</i> , 2019)	Develops a tool for clinicians to appropriately prescribe antibiotics (pneumonia in the ICU)
(Leibovici <i>et al.</i> , 2000)	Develops a tool for clinicians to appropriately prescribe antibiotics (UTI patients)
(Beuscart <i>et al.</i> , 1999)	Develops a tool for clinicians to appropriately prescribe antibiotics (UTI patients)
(Andreassen <i>et al.</i> , 1999)	Decision tool to balance therapeutic benefit and cost of antibiotics (UTI patients)

analysis

n= 5

Both n= 1

Decision  
tool n= 6

meat production

Hospital setting

# Review of BBNs in the field of AMR: dealing with incomplete data with non-learnt structures

## A Causal Probabilistic Network for Optimal Treatment of Bacterial Infections

Leonard Leibovici, Michal Fishman, Henrik C Schönheyder, Christian Riekehr, Brian Kristensen, Ilana Shraga, and Steen Andreassen

For our purposes, factor analysis offers a number of advantages. The donation of correlated variables is counted just once. Many times, the common factors correspond to a real biological vector. It also reduces the problem of missing data while using the system. (If a factor causes a number of

## A probabilistic and decision-theoretic approach to the management of infectious disease at the ICU

Peter J.F. Lucas <sup>a,\*</sup>, Nicolette C. de Bruijn <sup>b</sup>, Karin Schurink <sup>c</sup>, Andv Hoenelman <sup>c</sup>

The models were built on the basis of expert knowledge. The patient data that were available were of limited value in the initial construction of the models because of problems of incompleteness. In particular, detailed temporal information was missing. By means of a

Predicting the causative pathogen among children with osteomyelitis using Bayesian networks – improving antibiotic selection in clinical practice

Yue Wu<sup>a,\*</sup>, Charlie McLeod<sup>a,b,c</sup>, Christopher Blyth<sup>a,b,c,d</sup>, Asha Bowen<sup>a,c</sup>, Andrew Martin<sup>b,e</sup>, Ann Nicholson<sup>f</sup>, Steven Mascaro<sup>f,g</sup>, Tom Snelling<sup>a,c,h,i</sup>

We established the CPTs through a knowledge engineering-based method, generating three models. We use the expectation maximization (EM) algorithm [40] to learn parameters for the latent variable for its ability to deal with missing data. In addition, we pre-set values for the latent variable if sufficient evidence is available. For example, *S. aureus* is entered if it was isolated by all three tests.

## Transferability modelling in the TREAT decision support system

Alina Zalounina\*, Steen Andreassen\*,  
Leonard Leibovici\*\*, Mical Paul\*\*

Future efforts should be invested in optimising the process for calibrating distribution of pathogens. The collection of data for calibrating pathogens is a complex and time consuming process. The full data for prevalences of pathogens given risk factors are available only in an environment in which a full patient electronic file is kept, and the diagnoses of sites of infection must be linked to bacteriological results. But even in such an environment data might be biased by missing data (e.g. of hospital acquired

# Review of BBNs in the field of AMR: dealing with incomplete data with learnt structures

## Revealing antibiotic cross-resistance patterns in hospitalized patients through Bayesian network modelling

Stacey S. Cherny<sup>1,2</sup>, Daniel Nevo<sup>3</sup>, Avi Baraz<sup>1,2,3</sup>, Shoham Baruch<sup>1,2</sup>, Ohad Lewin-Epstein<sup>4</sup>, Gideon Y. Stein<sup>5,6</sup> and Uri Obolski<sup>1,2\*</sup>

We selected the antibiotics to include in the analysis by keeping only those with minimal missing data and those that did not reduce the number of complete cases appreciably (<10% loss). We performed some variable selection to assure stable statistical models with no perfect or near-perfect

## Additive Bayesian networks for antimicrobial resistance and potential risk factors in non-typhoidal *Salmonella* isolates from layer hens in Uganda

Sonja Hartnack<sup>1\*†</sup>, Terence Odoch<sup>2†</sup>, Gilles Kratzer<sup>3</sup>, Reinhard Furrer<sup>3,4</sup>, Yngvild Wasteson<sup>5</sup>, Trine M. L'Abée-Lund<sup>5</sup> and Eystein Skjerve<sup>5</sup>

The entire statistical analysis was conducted using **R** [21]. As ABN requires a complete dataset, under the assumption of missing at random, missing values were imputed with the R package *missforest* [22]. ABN analysis was performed with the R package *abn* [23]. Here,




- Introduce missing data and three missing mechanisms
- A brief review on how BBNs can be used for dealing with missing data
- Demonstrate a simulation study on comparing the performance of two popular approaches for missing data
- Demonstrate an application on real data - case study of AMR








# ?

# Missing Data




A	B	C
5	10	?
4	?	6




# Missing Mechanisms

- MCAR - Missing Completely at Random (rare)  
-- missingness is **unrelated** to unobserved & observed responses
- MAR – Missing at Random (common)  
-- missingness is **unrelated** to unobserved response but **related** to observed response
- MNAR – Missing Not at Random (difficult to detect)  
-- missingness is **related to both** unobserved and observed responses




# Bayesian Networks & Missing Data

- Structure learning from incomplete data
  - data completion & refinement + standard learning algorithms & scores (e.g., Structural EM algorithm)
  - approximate BIC scores & marginal likelihood  $P(D|G)$  (e.g., variational-Bayesian EM algorithm)
- Parameter learning from incomplete data given a known structure (assume MCAR or MAR)
  - data augmentation (DA; Tanner & Wong, 1987)
  - expectation–maximisation algorithm (EM; Lauritzen, 1995)
  - Bound and Collapse (also robust for MNAR data) [BC; Ramoni & Sebastiani, 1997]
  - robust Bayesian estimator (RBE; Ramoni & Sebastiani)
  - simple imputation methods (Oni'sko, Druzdzal, & Wasyluk, 2002)



# Structural Expectation- Maximization (SEM)




Random Network Structure



Compute Expected sufficient statistics

A	B	C
1	??	34
26	8	19

Incomplete Data



Search for a BN structure that maximises the expected score function


Replace


Update

A	B	C
1	77	34
26	8	19

Completed Data

Converge





# Multiple Imputation by Chained Equations (MICE)

A	B	C
14	?	1001
13	3	998
?	1	345
56	9	?

incomplete data

impute  
all values

A	B	C
14	3	1001
13	3	998
13	1	345
56	9	998

impute  
each variable

A	B	C
14	3	1001
13	3	998
?	1	345
56	9	998

Impute missingness in **A**  
by making use of other  
observations (e.g. linear  
regression model)

After Imputing missingness  
in variable **A**, **B** & **C** (one by one)

A	B	C
14	5	1001
13	3	998
21	1	345
56	9	2009

Replace

minus

We can create several copies of the  
original incomplete data set. Each  
copy will be processed in iterations.  
Then we can choose to analyse all  
the completed data sets together or  
combine the statistical results of  
each completed data set.

The iteration stops  
until reaching a pre-  
defined threshold

||

A	B	C
0	-2	0
0	0	0
-8	0	0
0	0	-11

difference matrix


Update






Compare the performance of  
SEM and MICE

# Simulation Study




- Variables: 2 to 20
- Data points: 1000, 5000, 10000
- Missing proportion: 0.1 to 0.6 at intervals of 0.1
- Each condition is repeated 100 times.


Original BN




None




SEM



MICE






Data points: 1000

**MNAR** Data


**A.** Precision =  $\frac{TP}{TP+FP}$

**B.** Recall =  $\frac{TP}{TP+FN}$

Statistical tests: One-way ANOVA, Tukey's HSD pairwise tests, \*,  $p < 0.05$ ; \*\*,  $p < 0.01$ ; \*\*\*,  $p < 0.001$ ; \*\*\*\*,  $p < 0.0001$



MNAR – Recall




Comparison across three levels of data points.

MNAR Data

$$\text{Recall} = \frac{TP}{TP+FN}$$

Statistical tests: One-way ANOVA, Tukey’s HSD pairwise tests, \*, p < 0.05; \*\*, p < 0.01; \*\*\*, p < 0.001; \*\*\*\*, p < 0.0001

Difference of Recall Mean across Three Levels of Data points




MNAR Data

# Conclusion

- Both SEM and MICE  $\uparrow$  the completeness of Bayesian network structure learned from incomplete dataset.
- In some circumstances (e.g., data with high missing proportion and high number of variables), the performance of SEM algorithm  $>$  MICE.
- When there are low number of data points, the outperformance of SEM over the other two methods  $\uparrow$  with  $\uparrow$  number of variables and  $\uparrow$  missing proportion.
- The outperformance of SEM and MICE over doing nothing decreases  $\downarrow$  when there are high number of data points.





# Case study on AMR data



University of  
St Andrews

FOUNDED  
1413



Holistic Approach To  
Unravel Antibacterial  
Resistance in East Africa

Holistic approach to unravel  
antibacterial resistance in East  
Africa (HATUA)



UK Research  
and Innovation

Variables (13)	Description	Levels
gender	Gender of each patient	"Male" , "Female"
age	Age of each patient	"<35", "35-64", "65 and above", NA
health_cost	How has it been for the patient to meet the cost of your own healthcare needs in the last 12 months?	"Very difficult", "little difficult", "Easy", NA
hospital_level	From which level of hospital has the patient been recruited?	"high", "low"
self_treatment	How did the patient first seek treatment?	"Non Self-treatment", "Self-treatment", NA
antibiotic_taking	What drugs did the patient take while seeking treatments?	"Yes antibiotic consumption", "No antibiotic consumption", NA
steps_pathway	The UTI pathway steps that patients took in seeking treatments.	"complex pathway: 2+ steps", "simple pathway: 0/1 step", NA
doctor_prescript	Did doctors give the patient a prescription (line) for antibiotics?	"no", "yes", NA
medicine_taking	What kind of medicines did the patient take for subsequent treatment?	"No medicine", "AB suitable for UTI", "Other AB", NA
see_doctor	Have the patient ever been to the doctor /hospital/health worker for these kinds of symptoms in the past?	"Yes", "No", NA
genus	The species that have been identified from the urine samples.	"Determined bacteria", "Undetermined bacteria", NA
gram_reaction	The gram reaction of species identified from the urine samples.	"negative", "positive", NA
MDR	Whether the patient has multiple drug resistance (MDR) infection.	"yes", "no", NA


“Multiple drug resistance (MDR), multidrug resistance or multi-resistance is AMR shown by a species of microorganism to at least one antimicrobial drug in three or more antimicrobial categories. ”

**Table 2A-1. (Continued)**

Test/Report Group	Antimicrobial Agent	Disk Content	Zone Diameter Interpretive Criteria (nearest whole mm)			
			S	SDD	I	R
PENICILLINS						
A	Ampicillin	10 µg	≥ 17	–	14–16	≤ 13
O	Piperacillin	100 µg	≥ 21	–	18–20	≤ 17
O	Mecillinam	10 µg	≥ 15	–	12–14	≤ 11
β-LACTAM/β-LACTAMASE INHIBITOR COMBINATIONS						
B	Amoxicillin-clavulanate	20/10 µg	≥ 18	–	14–17	≤ 13
B	Ampicillin-sulbactam	10/10 µg	≥ 15	–	12–14	≤ 11
B	Ceftolozane-tazobactam	–	–	–	–	–
B	Piperacillin-tazobactam	100/10 µg	≥ 21	–	18–20	≤ 17
O	Ticarcillin-clavulanate	75/10 µg	≥ 20	–	15–19	≤ 14




Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, Harbarth S, Hindler JF, Kahlmeter G, Olsson-Liljequist B, Paterson DL, Rice LB, Stelling J, Struelens MJ, Vatopoulos A, Weber JT, Monnet DL. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect. 2012 Mar;18(3):268-81. doi: 10.1111/j.1469-0691.2011.03570.x. Epub 2011 Jul 27. PMID: 21793988. <https://onlinelibrary.wiley.com/doi/pdf/10.1111/j.1469-0691.2011.03570.x>




Distribution  
of Missing  
Values

## Missing Patterns


- Observations N = 2261
- Complete cases N = 1067




Complete cases





SEM













# Conclusion

- SEM algorithm identified factors associated with multiple-drug resistance
  - Genus of bacteria that infected patients
  - Type of bacteria (gram - positive or negative)
  - Gender of patients
  - Patient's age
  - Whether patients have been provided the prescription of antibiotics from doctors
  - The hospital level that patients have been to seek treatments

To be continued...



# Acknowledgement

- Dr V Anne Smith
- Dr Katherine Keenan



University of  
St Andrews



Scottish  
Graduate  
School of  
Social  
Science



UK Research  
and Innovation



**H**olistic **A**pproach **T**o  
**U**n unravel **A**ntibacterial  
Resistance in East Africa



THANKS FOR LISTENING!



ANY QUESTIONS?